Genedrive PLC Grant of options (3632U)
02 December 2021 - 8:44PM
UK Regulatory
TIDMGDR
RNS Number : 3632U
Genedrive PLC
02 December 2021
genedrive plc
("genedrive" or the "Company")
Grant of Options
genedrive plc (LSE: GDR), the near patient molecular diagnostics
company, announces that on 2 December 2021 share options
("Options") were granted to members of its senior management team
to acquire a total of 400,000 ordinary shares of 1.5p each
("Ordinary Shares") in the Company under the Company's Share Option
Scheme.
The Options have been granted with an exercise price of 31p
being equal to the closing price on the day before the grant and
vest after a period of three years, subject to certain performance
criteria being met through achieving revenue and other financial
targets, as well as completing certain strategic projects in the
year ending 30 June 2024. The Options are exercisable over the
period of 10 years from the date of grant.
The information set out below is provided in accordance with the
requirements of Article 19(3) of the EU Market Abuse Regulation No
596/2014.
1. Details of the person discharging managerial responsibilities
/ person closely associated
a. Name 1. Alex Mann
2. Jonathan Barber
3. Gino Miele
4. Colleen Phythian
----------------------- -----------------------------------------------
2. Reason for the notification
------------------------------------------------------------------------
a. Position/status 1. Commercial Director
2. Operations Director
3. R&D Director
4. Director of Quality & Regulation
----------------------- -----------------------------------------------
a. Initial notification Initial notification
/Amendment
----------------------- -----------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------
a. Name genedrive plc
----------------------- -----------------------------------------------
b. LEI 213800ZYODIRZ87Y4K14
----------------------- -----------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------
a. Description Options over ordinary shares of 1.5 pence
of the each
Financial instrument,
type
of instrument
Identification GB00B1VKB244
code
----------------------- -----------------------------------------------
b. Nature of the Grant of options pursuant to and in accordance
transaction with the terms of the Company's Share Option
Scheme dated 29 November 2017
----------------------- -----------------------------------------------
c. Price(s) and
volume(s)
PDMR Exercise No of Options
price
--------- --------------
Alex Mann 31p 100,000
--------- --------------
Jonathan
Barber 31p 100,000
--------- --------------
Gino Miele 31p 100,000
--------- --------------
Colleen
Phythian 31p 100,000
--------- --------------
----------------------- -----------------------------------------------
d. Aggregated
information N/A
Aggregated
volume
Price
----------------------- -----------------------------------------------
e. Date of the 2021-12-02
transaction
----------------------- -----------------------------------------------
f. Place of the Outside a trading venue
transaction
----------------------- -----------------------------------------------
For further details please contact:
genedrive plc +44 (0)161 989 0245
David Budd: CEO / Matthew Fowler: CFO
Peel Hunt LLP (Nominated Adviser and
Joint Broker) +44 (0)20 7418 8900
James Steel
finnCap (Joint Broker) +44 (0)20 7220 500
Geoff Nash / Kate Bannatyne / Alice
Lane
Walbrook PR Ltd (Media Relations & +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Investor Relations)
Paul McManus / Anna Dunphy +44 (0)7980 541 893 / +44 (0)7876
741 001
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHEANAAEDPFFEA
(END) Dow Jones Newswires
December 02, 2021 04:44 ET (09:44 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2023 to Apr 2024
